- Industry veteran brings extensive senior level leadership and expertise in biologics development, strategic partnerships, mergers and acquisitions across biotech…
Grand Cayman, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology…
Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention…
The digital pathology market is anticipated to increase due to the global increase in chronic conditions like cancer, cardiovascular disorders,…
DELRAY BEACH, Fla., Sept. 1, 2025 /PRNewswire/ -- The global Contract Research Organization Services Market, valued at US$79.10 billion in…
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS…
Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded…
ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis…
Illustrative image Laboratory, Boehringer Ingelheim This press release is not intended for UK and US media. HERNEXEOS® (zongertinib tablets) has been…
Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American…